로딩 중…
StockDiggingStockDigging

GC Biopharma Corp.

006280· KOSPI
₩124,700-4.52%
2026-06-19

Price Chart

GC Biopharma Corp.-2.81%

Financials

Investment Metrics(as of 2026-06-19)

MetricValue
Size
Market Cap1.46T KRW
Revenue2.04T KRW
Net Income-39.24B KRW
Total Assets2.97T KRW
Net Assets1.39T KRW
Employees2,355
Value
P/B1.05x
P/S0.71x
EV/EBITDA31.25x
FCF Yield1.86%
Profitability
ROE-2.81%
ROA-1.32%
Op. Margin3.57%
Revenue Growth13.49%
Earnings Growth-32.17%
Financial Health
Debt Ratio113.09%
Total Debt862.25B KRW
FCF27.10B KRW
Cash40.73B KRW
Current Ratio1.25x
Net Debt/EBITDA11.27x
Dividend
Div. Yield1.15%
Div. Growth0.00%
Performance
1Y Return-2.81%
1M Return-3.78%
From 52W High-32.15%
1Y MDD-34.17%
Trading
Volume60,592 shares
Foreign Own.22.64%
Per Share
EPS-1,189 KRW
BPS107,655 KRW

Company Info

CEO 허은철
Employees 2,355
Founded 1969
HQ 경기도 용인시, KR

Established in 1969 and headquartered in Yongin-si, Gyeonggi-do, Green Cross is a professional pharmaceutical manufacturer and seller specializing in blood products and vaccine products. Its main businesses include blood products, general products, and vaccine products. The company strengthened its raw plasma procurement capabilities by acquiring US ABO Holdings in 2025 and is entering the global market with ALYGLO's US FDA approval and 2024 launch. Green Cross supplies products to domestic and international markets through its Ochang factory production facilities, aiming to become a global pharmaceutical company focused on key strategic products.